Please use this identifier to cite or link to this item:
Title: 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.
Authors: Quintela-Fandino, Miguel
Lluch, Ana
Manso, Luis
Calvo, Isabel
Cortes, Javier
García-Saenz, José Angel
Gil-Gil, Miguel
Martinez-Jánez, Noelia
Gonzalez-Martin, Antonio
Adrover, Encarna
de Andres, Raquel
Viñas, Gemma
Llombart-Cussac, Antonio
Alba, Emilio
Guerra, Juan
Bermejo, Begoña
Zamora, Esther
Moreno-Anton, Fernando
Pernas Simon, Sonia
Carrato, Alfredo
Lopez-Alonso, Antonio
Escudero, María José
Campo, Ruth
Carrasco, Eva
Palacios, José
Mulero, Francisca
Colomer, Ramon
metadata.dc.subject.mesh: Adult
Aged, 80 and over
Breast Neoplasms
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Positron Emission Tomography Computed Tomography
Protein Kinase Inhibitors
Receptor, ErbB-2
Tumor Hypoxia
Issue Date: 1-Sep-2016
Abstract: Purpose: We previously detected promising efficacy of neoadjuvant nintedanib (a multityrosine kinase inhibitor, TKI) in early HER2-negative breast cancer. In a preclinical study, we monitored stromal hypoxia with 18F-fluoromisonidazole-positron emission tomography (18F-FMISO-PET); we found that reoxygenation of tumors (or lack of it) during a window-of-opportunity (WoO) treatment with TKIs correlated with the benefit (or lack of it) from TKI-plus-chemotherapy combinations. We studied the predictive role of 18F-FMISO-PET for the TKI nintedanib in the neoadjuvant setting in a phase II WoO randomized trial.Experimental Design: Patients were randomized to a 14-day WoO of nintedanib preceded and followed by an 18F-FMISO-PET, followed by nintedanib plus weekly paclitaxel (Arm A) or an 18F-FMISO-PET followed by weekly paclitaxel (Arm B) before surgery. The endpoint was residual cancer burden (RCB). The objective was to detect the patients with no response (RCB-III) on the basis of the baseline or evolutive 18F-FMISO-PET values/changes.Results: One-hundred and thirty HER2-negative patients were randomized. Seventeen (27.9%), 34 (55.7%), and 8 (13.1%) patients had an RCB of III, II, and I/0, respectively, in Arm A. In this arm, baseline hypoxic tumors had a 4.4-fold higher chance of experiencing RCB = 3 (P = 0.036) compared with baseline normoxic tumors. Nintedanib WoO induced tumor reoxygenation in 24.5% of the patients; those not reoxygenating showed a trend toward higher chance of experiencing RCB-III (6.4-fold; P = 0.09). In Arm B, 18F-FMISO-PET lacked predictive/prognostic value.Conclusions: Baseline hypoxic tumors (measured with 18F-FMISO-PET) do not benefit from neoadjuvant nintedanib. Clin Cancer Res; 23(6); 1432-41. ©2016 AACR.
metadata.dc.identifier.doi: 10.1158/1078-0432.CCR-16-0738
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.